SHUKRAPHARShukra Pharmaceuticals Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Shukra Pharmaceuticals Limited manufactures and markets pharmaceutical products in India and internationally. Its product portfolio includes macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-anthelmintic, sedative and tranquillizer, anti-depressant, anti-manic, anti-emetic, anti-ulcer, beta blockers, diuretics, analgesic, muscle relaxants, anti-tuberculosis, vitamin products, anti-allergics, corticosteroids, hyper and hypoglycemic, and other products, as well as antibiotics, such as penicillin and cephalosporin. The company was formerly known as Relish Pharmaceuticals Limited and changed its name to Shukra Pharmaceuticals Limited in August 2016. Shukra Pharmaceuticals Limited was incorporated in 1993 and is based in Ahmedabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on SHUKRAPHAR — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why buy
- • Revenue growth: 336.3% YoY
- • Profit growth: 1400.0% YoY
- • ROE: 24.6%
- • RSI: 60
- • Price vs EMA21: above
- • Price vs SMA50: above
Bull case
- • Revenue growth: 336.3% YoY
- • Profit growth: 1400.0% YoY
- • ROE: 24.6%
- • RSI: 60
Bear case
- • Valuation vs sector: P/E 86.5 vs sector 35.5
- • Dividend yield: 0.02%
- • MACD: bearish
- • Sector momentum: sector -10.0% (1m)
Key risks
- • Valuation vs sector: P/E 86.5 vs sector 35.5
- • Dividend yield: 0.02%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹4.70). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.